Ligandpro platform for screening small molecule-protein interactions in PROTAC development
Interplay Bio's LigandPro platform enables high-throughput screening of small molecule-protein interactions to develop PROTACs, molecular glues, and drug conjugates. This technology aids in identifying therapeutic targets for diseases like cancer and neurodegenerative disorders.
Overview
Interplay Bio introduces the LigandPro platform, a groundbreaking technology designed to facilitate the discovery and development of Proteolysis Targeting Chimeras (PROTACs). This platform is target agnostic and excels in high-throughput screening to identify interactions between small molecules and proteins of interest. By leveraging this technology, the platform not only aids in the development of PROTACs but also extends to molecular glues, Lytacs, Autacs, and small molecule drug conjugates, targeting a range of diseases including cancer, virology, tuberculosis, and neurodegenerative disorders.
Technical specifications
The LigandPro platform is engineered to identify small molecule-protein interactions efficiently. It screens small molecule libraries to discover their interacting partners, with an emphasis on binding affinity, selectivity, and physical-chemical properties. The platform uses commercially available E3 ligase binders and linkers to synthesize PROTACs. Key features include:
- Target agnostic high-throughput screening
- Screening capabilities for molecular glues and drug conjugates
- Utilization of known E3 ligase binders for PROTAC synthesis
- Ternary complex assays for molecular glue validation
Technology readiness level
The LigandPro platform is at Technology Readiness Level 3. Initial proof of concept has been validated by screening ten small molecules, identifying proteins involved in various diseases. Future work will focus on synthesizing PROTACs and validating molecular glue interactions using the platform's proprietary assays.
About Interplay Bio
Interplay Bio is a biotechnology company that accelerates the development of targeted protein degrader (TPD) drugs using its proprietary LigandPro platform. The company utilizes a protein-agnostic, unbiased screening approach to identify novel small molecule-target interactions. By mapping polypharmacology across a wide array of proteins, including those previously considered undruggable, the platform detects transient and low-affinity interactions to identify hit compounds. This approach is designed to be more cost-effective and faster than traditional high-throughput screening methods, enabling the discovery of new E3 ligase binders, molecular glues, and therapeutic targets.
The platform is used to support pharmaceutical partnerships for lead optimization and drug discovery in therapeutic areas such as oncology, neurodegenerative diseases, and metabolic disorders. By exploiting existing molecule libraries to uncover new protein-small molecule interactions, the company helps partners develop more effective and safer therapeutic candidates. Interplay Bio provides services for target ligand discovery and the development of proprietary binders and molecular glues, leveraging its pipeline of small molecule-protein interactions to advance innovative treatments into clinical stages.
delivered to your inbox.